Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics


Viking Therapeutics, Inc. (VKTX): $6.69

0.12 (+1.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VKTX Stock Price Chart Interactive Chart >

Price chart for VKTX

VKTX Price/Volume Stats

Current price $6.69 52-week high $10.09
Prev. close $6.57 52-week low $4.95
Day low $6.50 Volume 2,212,200
Day high $6.91 Avg. volume 1,058,090
50-day MA $6.13 Dividend yield N/A
200-day MA $6.36 Market Cap 523.09M

Viking Therapeutics, Inc. (VKTX) Company Bio


Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.


VKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

VKTX Latest Social Stream


Loading social stream, please wait...

View Full VKTX Social Stream

Latest VKTX News From Around the Web

Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.

Viking Therapeutics to Participate in Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in four upcoming investor conferences.

Yahoo | September 2, 2021

What Type Of Shareholders Own The Most Number of Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

If you want to know who really controls Viking Therapeutics, Inc. ( NASDAQ:VKTX ), then you'll have to look at the...

Yahoo | August 30, 2021

Viking Therapeutics (VKTX) Q2 2021 Earnings Call Transcript

Joining me today is Brian Lian, Viking's president and CEO; and Greg Zante, Viking's CFO. Today, we'll provide an overview of our second-quarter 2021 financial results, as well as an update on recent progress and developments with our pipeline programs and operations.

Yahoo | July 30, 2021

Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2021, and provided an update on its clinical pipeline and other corporate developments.

Yahoo | July 28, 2021

Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2021, after the market close on Wednesday, July 28, 2021.

Yahoo | July 21, 2021

Read More 'VKTX' Stories Here

VKTX Price Returns

1-mo 15.34%
3-mo 10.21%
6-mo 16.55%
1-year -2.19%
3-year -63.24%
5-year 418.60%
YTD 18.83%
2020 -29.80%
2019 4.84%
2018 88.42%
2017 241.18%
2016 -65.10%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7724 seconds.